Skip to main content
SpringerLink
Log in

L-Asparaginase—Based Regimen in the Treatment of Refractory Midline Nasal/Nasal-Type T/NK-Cell Lymphoma

  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Nasal, nasal-type T-cell/natural killer cell (T/NK-cell) lymphoma is a rare disease, and its prognosis is poor. Between March 1992 and March 2002 we investigated a new L-asparaginase-based salvage regimen to treat the disease and improve response to treatment and 5-year overall survival rate. Eighteen patients with refractory midline nasal, nasal-type T/NK-cell lymphoma, who were resistant to a cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)-like regimen, received an L-asparaginase—based salvage regimen (L-asparaginase, vincristine, and dexamethasone). Primary involved field radiation was given to the patients after chemotherapy.Ten (55.6%) of the patients achieved complete response (CR). Five patients (27.8%) achieved partial response (PR).The overall response rate (CR + PR) was 83.3%.The 5-year overall survival rate was 55.6%. Results of the preliminary clinical study indicated that the L-asparaginase—based salvage regimen significantly improved the response rate and 5-year survival rate.The findings suggested that the therapy is a promising new salvage regimen for treating refractory midline nasal, nasal-type T/NK-cell lymphoma. Int J Hematol. 2003;78:163-167.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Liang R,Todd D, Chan TK, et al.Treatment outcome and prognostic factors for primary nasal lymphoma.J Clin Oncol. 1995;13:666–670.

    Article  PubMed  CAS  Google Scholar 

  2. Cheung MMC, Chan JKC, Lau WH, et al. Primary non-Hodgkin’s lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients.J Clin Oncol. 1998;16:70–77.

    Article  PubMed  CAS  Google Scholar 

  3. Cheung MM, Chan JK, Lau WH, et al. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality.Int J Radiat Oncol Biol Phys. 2002;54:182–190.

    Article  PubMed  Google Scholar 

  4. Ko YH, Ree HJ, Kim WS, et al. Clinicopathologic and genotypic study of extranodal nasal-type natural killer/T-cell lymphoma and natural killer precursor lymphoma among Koreans.Cancer. 2000; 89:2106–2116.

    Article  PubMed  CAS  Google Scholar 

  5. Kinney MC. The role of morphologic features, phenotype, genotype, and anatomic site in defining extranodal T-cell or NK-cell neoplasms.Am J Pathol. 1999;111(suppl 1):s104-s118.

    CAS  Google Scholar 

  6. Tao Q, Ho FCS, Loke SL, et al. Epstein-Barr virus is localized in the tumor cells of nasal lymphoma of NK, T or B cell type.Int J Cancer. 1995;60:315–320.

    Article  PubMed  CAS  Google Scholar 

  7. Kim WS, Song SY, Ahn YC, et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma?Ann Oncol. 2001;12:349–352.

    Article  PubMed  CAS  Google Scholar 

  8. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with 3 intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma.N Engl J Med. 1993;328:1002–1006.

    Article  PubMed  CAS  Google Scholar 

  9. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment.Cancer. 1981;47:207–214.

    Article  PubMed  CAS  Google Scholar 

  10. Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive non-Hodgkin’s lymphoma.N Engl J Med. 1993;329:987–994.

    Article  Google Scholar 

  11. Jaffe ES. Introduction to the WHO classification.Am J Surg Pathol. 1997;21:114–121.

    Article  Google Scholar 

  12. Jaffe ES, Krenacs L, Kumar S, et al. Extranodal peripheral T-cell and NK-cell neoplasms.Am J Clin Pathol. 1999;111(suppl):s46-s55.

    PubMed  CAS  Google Scholar 

  13. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group.Blood. 1994;84:1361–1392.

    PubMed  CAS  Google Scholar 

  14. Yamaguchi M, Kita, K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells.Cancer. 1995;76:2351–2356.

    Article  PubMed  CAS  Google Scholar 

  15. Fauci AS,Wolff SM. Radiation therapy of midline granuloma.Ann Intern Med. 1976;84:140–147.

    Article  PubMed  Google Scholar 

  16. Campo E, Cardesa A, Alos L, et al. Non-Hodgkin’s lymphomas of nasal cavity and paranasal sinuses: an immunohistochemical study.Am J Clin Pathol. 191;96:184–190.

    Article  PubMed  CAS  Google Scholar 

  17. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes.Blood. 1992;80:2735–2739.

    PubMed  CAS  Google Scholar 

  18. Nagafuji K, Fujisaki T, Arima F, et al. L-asparagine induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation.Int J Hematol. 2001;74:447–450.

    Article  PubMed  CAS  Google Scholar 

  19. Codegoni AM, Biondi A, Conter V, et al. Human monocytic leukemia expresses low levels of asparagine synthase and is potentially sensitive to L-asparaginase.Leukemia. 1995;9:360–361.

    PubMed  CAS  Google Scholar 

  20. Sherf U, Ross DT, Waltthom M, et al. A gene expression data base for the molecular pharmacology of cancer.Nat Genet. 2000;24:236–244.

    Article  CAS  Google Scholar 

  21. Kitob T, Nisbimura S, Shirahase H, et al. Immunocytochemical analysis of asparagine synthetase protein of leukemia cells: indication for L-asparaginase treatment.Blood. 1996;88(suppl 1):86a.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology Beijing Cancer Hospital The School of Oncology, Peking University, 52 Fucheng Road, Beijing, PR China

    Weiben Yong, Wen Zheng, Yuntao Zhang, Jun Zhu, Yan Wei & Deliang Zhu

  2. Pathology, Beijing Cancer Hospital, School of Oncology, Peking University, Beijing, People’s Republic of China

    Jiyou Li

Authors
  1. Weiben Yong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wen Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuntao Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jun Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yan Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Deliang Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jiyou Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Weiben Yong.

About this article

Cite this article

Yong, W., Zheng, W., Zhang, Y. et al. L-Asparaginase—Based Regimen in the Treatment of Refractory Midline Nasal/Nasal-Type T/NK-Cell Lymphoma. Int J Hematol 78, 163–167 (2003). https://doi.org/10.1007/BF02983387

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02983387

Key words

Search

Navigation